Aerovate Therapeutics, Inc. (AVTE)

Market Cap	46.69M
Revenue (ttm)	n/a
Net Income (ttm)	-82.19M
Shares Out	28.82M
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	764,993
Open	1.720
Previous Close	1.700
Day's Range	1.615 - 1.725
52-Week Range	1.250 - 32.415
Beta	1.30
Analysts	Hold
Price Target	11.75 (+625.31%)
Earnings Date	Aug 12, 2024

About AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 30, 2021
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTE

Analyst Forecast

According to 7 analysts, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $11.75, which is an increase of 625.31% from the latest price.

Price Target

$11.75

(625.31% upside)

Analyst Consensus: Hold